Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ul...

Descripción completa

Detalles Bibliográficos
Autores: Marques-Pamies, M, Gil, J, Valassi, E, Hernández, M, Biagetti, B, Giménez-Palop, O, Martínez, S, Carrato, C, Pons, L, Villar-Taibo, R, Araujo-Castro, M, Blanco, C, Simón, I, Simó-Servat, A, Xifra, G, Vázquez, F, Pavón, I, García-Centeno, R, Zavala, R, Hanzu, FA, Mora, M, Aulinas, A, Vilarrasa, N, Librizzi, S, Calatayud, M, de Miguel, P, Alvarez-Escola, C, Picó, A, Sampedro, M, Salinas, I, Fajardo-Montañana, C, Cámara, R, Bernabéu, I, Jordà, M, Webb, SM, Marazuela, M, Puig-Domingo, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p16163
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/16163
Access Level:acceso abierto
Palabra clave:acromegaly
somatostatin analogs
prediction
individualized treatment
precision medicine
acute octreotide test
id ES_79892d4e2b445182f9f4a77d05afac67
oai_identifier_str oai:fisabio.fundanetsuite.com:p16163
network_acronym_str ES
network_name_str España
repository_id_str
spelling Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegalyMarques-Pamies, MGil, JValassi, EHernández, MBiagetti, BGiménez-Palop, OMartínez, SCarrato, CPons, LVillar-Taibo, RAraujo-Castro, MBlanco, CSimón, ISimó-Servat, AXifra, GVázquez, FPavón, IGarcía-Centeno, RZavala, RHanzu, FAMora, MAulinas, AVilarrasa, NLibrizzi, SCalatayud, Mde Miguel, PAlvarez-Escola, CPicó, ASampedro, MSalinas, IFajardo-Montañana, CCámara, RBernabéu, IJordà, MWebb, SMMarazuela, MPuig-Domingo, Macromegalysomatostatin analogspredictionindividualized treatmentprecision medicineacute octreotide testIntroduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was >= 3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively.Results: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 +/- 4.2 vs 3.3 +/- 2.1; p=0.01).Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.FRONTIERS MEDIA SA2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/16163Frontiers in EndocrinologyISSN: 16642392reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p161632026-06-11T12:45:17Z
dc.title.none.fl_str_mv Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
spellingShingle Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Marques-Pamies, M
acromegaly
somatostatin analogs
prediction
individualized treatment
precision medicine
acute octreotide test
title_short Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_full Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_fullStr Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_full_unstemmed Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
title_sort Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
dc.creator.none.fl_str_mv Marques-Pamies, M
Gil, J
Valassi, E
Hernández, M
Biagetti, B
Giménez-Palop, O
Martínez, S
Carrato, C
Pons, L
Villar-Taibo, R
Araujo-Castro, M
Blanco, C
Simón, I
Simó-Servat, A
Xifra, G
Vázquez, F
Pavón, I
García-Centeno, R
Zavala, R
Hanzu, FA
Mora, M
Aulinas, A
Vilarrasa, N
Librizzi, S
Calatayud, M
de Miguel, P
Alvarez-Escola, C
Picó, A
Sampedro, M
Salinas, I
Fajardo-Montañana, C
Cámara, R
Bernabéu, I
Jordà, M
Webb, SM
Marazuela, M
Puig-Domingo, M
author Marques-Pamies, M
author_facet Marques-Pamies, M
Gil, J
Valassi, E
Hernández, M
Biagetti, B
Giménez-Palop, O
Martínez, S
Carrato, C
Pons, L
Villar-Taibo, R
Araujo-Castro, M
Blanco, C
Simón, I
Simó-Servat, A
Xifra, G
Vázquez, F
Pavón, I
García-Centeno, R
Zavala, R
Hanzu, FA
Mora, M
Aulinas, A
Vilarrasa, N
Librizzi, S
Calatayud, M
de Miguel, P
Alvarez-Escola, C
Picó, A
Sampedro, M
Salinas, I
Fajardo-Montañana, C
Cámara, R
Bernabéu, I
Jordà, M
Webb, SM
Marazuela, M
Puig-Domingo, M
author_role author
author2 Gil, J
Valassi, E
Hernández, M
Biagetti, B
Giménez-Palop, O
Martínez, S
Carrato, C
Pons, L
Villar-Taibo, R
Araujo-Castro, M
Blanco, C
Simón, I
Simó-Servat, A
Xifra, G
Vázquez, F
Pavón, I
García-Centeno, R
Zavala, R
Hanzu, FA
Mora, M
Aulinas, A
Vilarrasa, N
Librizzi, S
Calatayud, M
de Miguel, P
Alvarez-Escola, C
Picó, A
Sampedro, M
Salinas, I
Fajardo-Montañana, C
Cámara, R
Bernabéu, I
Jordà, M
Webb, SM
Marazuela, M
Puig-Domingo, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acromegaly
somatostatin analogs
prediction
individualized treatment
precision medicine
acute octreotide test
topic acromegaly
somatostatin analogs
prediction
individualized treatment
precision medicine
acute octreotide test
description Introduction: We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) .Methods: A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was >= 3SDS, were considered non-responders. The 2 hours GH value (GH2h) after s.c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively.Results: In all, 30 patients were responders and 17 were non-responders. GH(2h) was 0.68 (0.25-1.98) ng/mL in responders vs 2.35 (1.59-9.37) ng/mL in non-responders (p<0.001). GH(2h) = 1.4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73.3%, and specificity of 94.1%). GH(2h) = 4.3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35.3%, and specificity of 96.7%). Patients with E-cadherin-positive tumors showed a lower GH(2h) than those with E-cadherin-negative tumors [0.9 (0.3-2.1) vs 3.3 (1.5-12.1) ng/mL; p<0.01], and patients with positive E-cadherin presented a higher score of SSTR2 (7.5 +/- 4.2 vs 3.3 +/- 2.1; p=0.01).Conclusion: The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/16163
url https://fisabio.portalinvestigacion.com/publicaciones/16163
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv FRONTIERS MEDIA SA
publisher.none.fl_str_mv FRONTIERS MEDIA SA
dc.source.none.fl_str_mv Frontiers in Endocrinology
ISSN: 16642392
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411356856287233
score 15,812429

Similares en LA Referencia